ABSTRACT
A commercial, lamb and rice, dog food with an omega-6:omega-3 fatty acid ratio of 5.5:1 was fed in a single-blinded, self-controlled clinical trial to 18 atopic dogs. The pruritus in 8 of these dogs (44.4%) was satisfactorily controlled within 7 to 21 d, returned within 3 to 14 d after the diet was withdrawn, and was again controlled when the diet was reinstated. Plasma and skin levels of examined fatty acids changed in all 18 dogs when their diet was switched to the test diet. Dogs responding to the test diet had a different pattern of fatty acid change as compared to the dogs which failed to respond to the diet, suggesting that there are subsets of atopic dogs with different fatty acid metabolism capabilities.
Subject(s)
Dermatitis, Atopic/veterinary , Diet/veterinary , Dog Diseases/diet therapy , Fatty Acids, Omega-3/therapeutic use , Fatty Acids, Unsaturated/therapeutic use , Pruritus/veterinary , Animals , Dermatitis, Atopic/diet therapy , Dermatitis, Atopic/metabolism , Dog Diseases/metabolism , Dogs , Dose-Response Relationship, Drug , Fatty Acids/analysis , Fatty Acids/blood , Fatty Acids/metabolism , Fatty Acids, Omega-3/administration & dosage , Fatty Acids, Omega-3/metabolism , Fatty Acids, Omega-6 , Fatty Acids, Unsaturated/administration & dosage , Fatty Acids, Unsaturated/metabolism , Female , Male , Meat/standards , Oryza/standards , Pruritus/diet therapy , Pruritus/metabolism , Sheep , Single-Blind Method , Skin/chemistrySubject(s)
Anti-Bacterial Agents/therapeutic use , Dog Diseases/drug therapy , Dog Diseases/etiology , Pyoderma/veterinary , Staphylococcal Skin Infections/veterinary , Staphylococcus , Tylosin/therapeutic use , Administration, Oral , Animals , Anti-Bacterial Agents/administration & dosage , Dogs , Dose-Response Relationship, Drug , Erythromycin/therapeutic use , Female , Male , Pyoderma/drug therapy , Pyoderma/etiology , Staphylococcal Skin Infections/complications , Tylosin/administration & dosageABSTRACT
The purpose of this study was to determine the efficacy of orally administered milbemycin oxime in the treatment of canine scabies. Forty dogs were treated. Mean drug dosage for all dogs was approximately 2 mg/kg body weight. Twenty-seven dogs received 3 doses separated by 7 d, and 13 dogs received 2 doses separated by 14 d. All dogs were clinically normal following treatment and no adverse reactions were detected.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Dog Diseases/drug therapy , Macrolides , Scabies/veterinary , Administration, Oral , Animals , Dogs , Drug Administration Schedule/veterinary , Female , Male , Scabies/drug therapy , Treatment OutcomeABSTRACT
OBJECTIVE: To determine the efficacy of increased dosages of milbemycin oxime in the treatment of generalized demodicosis. DESIGN: Prospective clinical trial. ANIMALS: 26 adult dogs with chronic generalized demodicosis. PROCEDURE: In phase 1, milbemycin was administered daily to 13 dogs at an approximate mean dosage of 1 mg/kg of body weight (PO) until 30 days after skin scrapings failed to detect mites. If the mite count had not decreased by 25% from the prior month's examination, the drug dosage was increased to approximately 2 mg/kg. Treatment was considered a failure if the mite count had not changed on 2 successive examinations. In phase 2 involving 13 other dogs, an approximate mean dosage of 2 mg/kg was used. If mite counts had not been reduced to 0 by 180 days, treatment was considered to have failed. RESULTS: In phase 1, when milbemycin was administered at the initial low dosage, 6 dogs were considered to have been cleared of mites. One of these relapsed 2 months after discontinuation of treatment. For the 7 dogs not cleared of mites, the dosage was doubled. Two of these were never cleared of mites. In phase 2, 12 of 13 dogs were cleared of mites after 60 to 180 days of treatment. CLINICAL IMPLICATIONS: High-dose milbemycin was effective in the treatment of generalized demodicosis.
Subject(s)
Anthelmintics/therapeutic use , Anti-Bacterial Agents/therapeutic use , Dog Diseases/drug therapy , Macrolides , Mite Infestations/veterinary , Animals , Anthelmintics/administration & dosage , Anti-Bacterial Agents/administration & dosage , Dogs , Dose-Response Relationship, Drug , Female , Male , Mite Infestations/drug therapy , Mites/growth & development , Recurrence , Skin/parasitology , Treatment FailureABSTRACT
Tylosin tablets (20 mg/kg, q12h) were administered orally to 21 dogs with superficial or deep staphylococcal pyodermas. Response to therapy was excellent in 90.5% of the dogs, and in vitro susceptibility testing correlated perfectly with therapeutic response. Duration of therapy varied from 17 to 91 days, with an average of 33 days. Relapses occurred in 28.6% of the dogs within a three-month period. No side effects were reported. Under the conditions of the study, tylosin was an effective and safe antibiotic for the treatment of staphylococcal pyoderma in dogs.
